Pharma execs pitch ideas at JPM20 to lower drug costs. None of them include dropping their own prices.

16 January 2020 - CEOs from the world’s largest pharmaceutical companies pitched ideas for lowering drug prices at the J.P. Morgan ...

Read more →

Aruvant receives FDA rare paediatric disease designation for ARU-1801 for the treatment of sickle cell disease

8 January 2020 - ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and ...

Read more →

New treatment approved in Canada for most common type of leukaemia

8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...

Read more →

Abuses of FDA regulatory procedures - the case of Suboxone

8 January 2020 - The manufacturer of brand-name buprenorphine products exploited various FDA regulatory procedures to impede market entry of generic ...

Read more →

AMCP Format for Formulary Submissions, Version 4.1, includes new dossiers for submitting evidence on unapproved medicines and unapproved indications submitted for FDA approval

8 January 2020 - AMCP has released Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new ...

Read more →

Focus needed not just on drugs but hospital expenses to impact health care costs

8 January 2020 - Much is made of the cost of drugs in the U. S., a topic that is ...

Read more →

Hospital overload ‘fuelled by GP rebate’

9 January 2020 - The Medicare rebate for GP consultatio­ns is too low, prompting tens of thousands of people each ...

Read more →

ReNetX Bio receives fast track designation from U.S. FDA

8 January 2020 - Potential first-in-class therapy for chronic spinal cord injury. ...

Read more →

Why Humira’s price keeps rising despite FDA approval of generic competition

8 January 2020 - The FDA has approved five generic versions of Humira — the world’s biggest-selling drug with global ...

Read more →

FDA is grappling with digital health regulation

8 January 2020 - The Food and Drug Administration announced this week it will hold a public meeting in late ...

Read more →

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer

8 January 2020 - On January 8, 2020, the Food and Drug Administration approved pembrolizumab (Keytruda) for the treatment of ...

Read more →

FDA – 2019 in review

8 January 2020 - Analysis of NDA approval timelines for 2019. ...

Read more →

GOP Sen. Grassley turns to House Speaker Pelosi for help selling his bipartisan drug pricing bill

7 January 2020 - Grassley said Tuesday he wants to persuade Pelosi to support his bill, which he argues is the ...

Read more →

PBAC – 2019 in review

8 January 2020 - The PBAC considered 188 submissions in 2019. ...

Read more →

AbbVie receives Health Canada approval of Rinvoq (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis

7 January 2020 - Approval supported by efficacy and safety data from the pivotal Phase 3 SELECT rheumatoid arthritis program, one ...

Read more →

Incyte announces the validation by the European Medicines Agency of its marketing authorisation application for pemigatinib in patients with cholangiocarcinoma

7 January 2020 - Incyte today announced the validation of the Company’s marketing authorisation application for pemigatinib for the treatment of ...

Read more →